Mr. David A. Ricks  
Chairman and Chief Executive Officer  
Eli Lilly and Company  
Eli Lilly and Company Corporate Center  
893 S. Delaware St.  
Indianapolis, IN 46225

Dear Mr. Ricks:

Pursuant to Rules X and XI of the U.S. House of Representatives, the Committee continues to explore issues surrounding patient access to affordable drug products, including insulin. The Committee is writing to follow up on our January 2019 letter to your company’s continued assistance in understanding the ongoing increase in insulin prices and the continued obstacles people living with diabetes face in accessing lifesaving medication.

When we last wrote to you in January 2019, we noted that the price of insulin had continually and unjustifiably skyrocketed over the past few decades. The Committee is troubled that despite your company’s expressions of shared concern, insulin prices in the United States remain unacceptably high. This is particularly frustrating considering Americans continue to bear a disproportionately high financial burden for their insulin compared to diabetes patients in other countries. One study showed that the average list price for insulin in the United States is

---


more than 10 times that of 33 other countries. While your 2020 pricing report states that you have not raised prices on your Humalog insulin product since 2017, it is not enough to simply maintain an unjustifiably high price for insulin.

Over 34 million Americans—10.5 percent of the United States population—have diabetes. Many of these individuals rely on insulin to stay alive and lead healthy lives. And while there have recently been some positive developments, including the approval of the first interchangeable biosimilar insulin product, the Committee remains concerned that many individuals suffering from diabetes are left without meaningful access to insulin due to its cost, despite the drug being available for approximately 100 years.

Furthermore, the coronavirus disease of 2019 (COVID-19) pandemic has exacerbated the struggles many diabetes patients experience to access health care and food in addition to the insulin that they need to maintain their health.

This Committee sent your company a letter on January 30, 2019 seeking information about the prices of your insulin products, the basis for the price of your products, and any efforts that your company had undertaken to ensure access to those requiring insulin. Your company’s February 13, 2019 response to that letter stated that “in recent years, we have recognized that there is an increased need to address patient affordability challenges as more patients bear a greater share of the costs of their medications” and that “as the insurance market

---


8 American Diabetes Association, The History of a Wonderful Thing We Call Insulin (www.diabetes.org/blog/history-wonderful-thing-we-call-insulin).


has evolved, Lilly has increasingly realized that not all patients have affordable access to insulin.”

In that same response, your company wrote that efforts were underway to provide a low-priced version of Humalog, one of Eli Lilly’s insulin products, to the market. That product entered the market on May 22, 2019, and the Committee is particularly interested to understand how that lower-priced version has affected the prices of your other insulin products and the insulin market generally.

Additionally, your Senior Vice President for Connected Care and Insulins, Michael B. Mason, also testified at the Committee’s hearing on April 10, 2019, on the rising cost of insulin. At that hearing, Mr. Mason stated that your company is concerned that “[t]oo many people today don’t have affordable access to chronic medications” and that some patients pay the high list price for insulin out-of-pocket.

We are committed to increasing access to affordable medicines and fighting the rising cost of insulin. Given your company’s representations in 2019 that this is a shared concern, we are interested in learning what has been done to alleviate this issue since that time. We therefore request that you provide the following information by September 17, 2021:

1. Please provide the annual prices, including list price and net price, of your marketed insulin products since January 2019. Please provide this information by product and by year.

2. To the extent any of your marketed insulin products have increased in price (either list price or net price) since January 2019, please provide an explanation for, and description of each price increase.

3. Please provide your gross revenue and net profit from each of your marketed insulin products since January 2019. Please provide this information by product and by year.

4. Please describe any research and development into your current or new insulin products since January 2019.

---


12 Id.


5. Please describe what steps your company has taken since January 2019 to increase patient access to insulin, including specifically any steps your company has taken to lower the cost of insulin since January 2019.

6. Please provide the following information regarding your patient assistance program, as it relates to your insulin products:

   a. A description of the process for a patient to enroll in your patient assistance program, including the documentation necessary for an applicant to be enrolled, average time from application to enrollment, and average time from enrollment until a patient sees a reduction in the out-of-pocket cost of their insulin;

   b. the number of individuals that have applied to your patient assistance program since January 2019;

   c. the number of individuals that have been enrolled in your patient assistance program since January 2019;

   d. the average reduction of out-of-pocket spending and the average remaining out-of-pocket spending by patients in your patient assistance program since January 2019; and

   e. the amount, if any, your company has claimed in tax deductions since January 2019 due to your patient assistance program.

7. Please describe whether the COVID-19 pandemic has affected your insulin products in any way, including manufacturing or supply challenges, alteration of planned pricing changes, or revisions to your patient access program.

8. Please provide an update on your efforts to market your low-priced version of Humalog, called Insulin Lispro Injection, introduced on May 22, 2019. Please include the annual sales volume of Insulin Lispro Injection by year since its launch as well as an explanation as to why you still market your higher-cost “identical medicine, Humalog U-100.”

16 Id.
Thank you for your prompt attention to this matter. If you have any questions, please contact Will McAuliffe with the Committee staff at (202) 594-6378.

Sincerely,

Frank Pallone, Jr.
Chairman

Diana DeGette
Chair
Subcommittee on Oversight and Investigations